Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Repka

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Frontiers in Oncology|April 24, 2023
Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failureJustin Leu, Meredith Akerman, Christopher Mendez, et al.
Frontiers in Oncology|April 24, 2023
Corrigendum: Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failureJustin Leu, Meredith Akerman, Christopher Mendez, et al.
Frontiers in Oncology|January 11, 2021
Stereotactic Body Radiation Therapy: A Versatile, Well-Tolerated, and Effective Treatment Option for Extracranial Metastases From Primary Ovarian and Uterine CancerNima Aghdam, Michael C Repka, Mary McGunigal, et al.
Frontiers in Oncology|February 27, 2024
High-risk prostate cancer treated with a stereotactic body radiation therapy boost following pelvic nodal irradiationJonathan W Lischalk, Meredith Akerman, Michael C Repka, et al.
Frontiers in Oncology|September 27, 2018
Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at RiskMichael C Repka, Siyuan Lei, Lloyd Campbell, et al.
Clinical Lung Cancer|December 29, 2016
Nine-year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small-cell Lung CancerDenise Bernhardt, Sebastian Adeberg, Farastuk Bozorgmehr, et al.
Frontiers in Oncology|June 1, 2016
Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose ReductionMichael C Repka, Shan Guleria, Robyn A Cyr, et al.
Frontiers in Oncology|April 8, 2024
Prognostic utility of biopsy-based <i>PTEN</i> and <i>ERG</i> status on biochemical progression and overall survival after SBRT for localized prostate cancerMichael C Repka, Tamir Sholklapper, Alan L Zwart, et al.
Frontiers in Oncology|April 18, 2022
Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate CancerMichael C Repka, Michael Creswell, Jonathan W Lischalk, et al.
JAMA Otolaryngology-- Head & Neck Surgery|April 23, 2026
Sustained Locoregional Control With Deintensified Chemoradiotherapy for HPV Oropharyngeal CarcinomaRyan T Morse, Ying Cao, Victoria Xu, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Frontiers in Oncology|April 24, 2023
Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failureJustin Leu, Meredith Akerman, Christopher Mendez, et al.
Frontiers in Oncology|April 24, 2023
Corrigendum: Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failureJustin Leu, Meredith Akerman, Christopher Mendez, et al.
Frontiers in Oncology|January 11, 2021
Stereotactic Body Radiation Therapy: A Versatile, Well-Tolerated, and Effective Treatment Option for Extracranial Metastases From Primary Ovarian and Uterine CancerNima Aghdam, Michael C Repka, Mary McGunigal, et al.
Frontiers in Oncology|February 27, 2024
High-risk prostate cancer treated with a stereotactic body radiation therapy boost following pelvic nodal irradiationJonathan W Lischalk, Meredith Akerman, Michael C Repka, et al.
Frontiers in Oncology|September 27, 2018
Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at RiskMichael C Repka, Siyuan Lei, Lloyd Campbell, et al.
Clinical Lung Cancer|December 29, 2016
Nine-year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small-cell Lung CancerDenise Bernhardt, Sebastian Adeberg, Farastuk Bozorgmehr, et al.
Frontiers in Oncology|June 1, 2016
Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose ReductionMichael C Repka, Shan Guleria, Robyn A Cyr, et al.
Frontiers in Oncology|April 8, 2024
Prognostic utility of biopsy-based <i>PTEN</i> and <i>ERG</i> status on biochemical progression and overall survival after SBRT for localized prostate cancerMichael C Repka, Tamir Sholklapper, Alan L Zwart, et al.
Frontiers in Oncology|April 18, 2022
Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate CancerMichael C Repka, Michael Creswell, Jonathan W Lischalk, et al.
JAMA Otolaryngology-- Head & Neck Surgery|April 23, 2026
Sustained Locoregional Control With Deintensified Chemoradiotherapy for HPV Oropharyngeal CarcinomaRyan T Morse, Ying Cao, Victoria Xu, et al.
Pageof 2